Novo Nordisk

Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Yahoo/Global Newswire
Novo Nordisk
FDA
Ozempic
type 2 diabetes
semaglutide
Flag link:
Pharma TV ad spenders blow up December with spendiest month of 2020
Pharma TV ad spenders blow up December with spendiest month of 2020
Fierce Pharma
television ads
AbbVie
Humira
Novo Nordisk
DTC ads
Flag link:
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Pharmaforum
Novo Nordisk
Dicerna
gene silencing
liver disease
Flag link:
Novo takes the plunge in Alzheimer’s
Novo takes the plunge in Alzheimer’s
EP Vantage
Novo Nordisk
Rybelsus
Alzheimer's disease
Flag link:
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Endpoints
Novo Nordisk
Novo Holdings
Hemab
hemophilia
Flag link:
Novo Nordisk to end 340B discounts on drugs dispensed at community pharmacies
Novo Nordisk to end 340B discounts on drugs dispensed at community pharmacies
Beckers Hospital Review
Novo Nordisk
340B
hospitals
Flag link:
Gilead and Novo plot next steps after trial data from NASH combo
Gilead and Novo plot next steps after trial data from NASH combo
Pharmaforum
Gilead Sciences
Novo Nordisk
NASH
clinical trials
semaglutide
cilofexor
firsocostat
Flag link:
Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal
Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal
Reuters
Novo Nordisk
M&A
Emisphere
pill technology
diabetes
Flag link:
AASLD 2020 – Nash updates from Novo and Inventiva in focus
AASLD 2020 – Nash updates from Novo and Inventiva in focus
EP Vantage
NASH
Novo Nordisk
Gilead Sciences
Inventiva
AASLD
selonsertib
Flag link:
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Endpoints
Novo Nordisk
earnings
NASH
semaglutide
breakthrough therapy
FDA
Flag link:
Novo Nordisk scraps Type 1 diabetes drug after phase 2 trial
Novo Nordisk scraps Type 1 diabetes drug after phase 2 trial
Fierce Biotech
Novo Nordisk
NN9828
Victoza
clinical trials
type 1 diabetes
Flag link:
Heart to heart: Novo Nordisk teams with ACC to open diabetes discussion
Heart to heart: Novo Nordisk teams with ACC to open diabetes discussion
Fierce Pharma
Novo Nordisk
pharma marketing
American College of Cardiology
patients
cardiovascular disease
Flag link:
Novo adds weight to its obesity goals
Novo adds weight to its obesity goals
EP Vantage
Novo Nordisk
semaglutide
obesity
Flag link:
Novo launches type 2 diabetes pill in UK after NICE waives review
Novo launches type 2 diabetes pill in UK after NICE waives review
Pharmaforum
Novo Nordisk
UK
type 2 diabetes
diabetes
Rybelsus
semaglutide
NICE
Flag link:
How did Novo Nordisk's Sophia chatbot become a pharma industry standard? Empathy, timing and relevance: experts
How did Novo Nordisk's Sophia chatbot become a pharma industry standard? Empathy, timing and relevance: experts
Fierce Pharma
Novo Nordisk
chatbot
digital pharma
Sophia
Flag link:
Novo Nordisk taps Evotec to target chronic kidney disease
Novo Nordisk taps Evotec to target chronic kidney disease
Fierce Biotech
Novo Nordisk
chronic kidney disease
Evotec
Flag link:
Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
Endpoints
Novo Nordisk
hemophilia
concizumab
clinical trials
Flag link:
Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections
Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections
Endpoints
drug development
antibiotics
F2G
Novo Nordisk
Flag link:
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes
Pharmaforum
Novo Nordisk
diabetes
digital pharma
digital medicine
Flag link:
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Fierce Biotech
Novo Nordisk
obesity
semaglutide
Flag link:

Pages